1
|
Sun Y, Peng I, Webster JD, Suto E, Lesch J, Wu X, Senger K, Francis G, Barrett K, Collier JL, Burch JD, Zhou M, Chen Y, Chan C, Eastham-Anderson J, Ngu H, Li O, Staton T, Havnar C, Jaochico A, Jackman J, Jeet S, Riol-Blanco L, Wu LC, Choy DF, Arron JR, McKenzie BS, Ghilardi N, Ismaili MHA, Pei Z, DeVoss J, Austin CD, Lee WP, Zarrin AA. Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response. Sci Signal 2015; 8:ra122. [PMID: 26628680 DOI: 10.1126/scisignal.aab0949] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Interleukin-2 (IL-2)-inducible T cell kinase (ITK) mediates T cell receptor (TCR) signaling primarily to stimulate the production of cytokines, such as IL-4, IL-5, and IL-13, from T helper 2 (TH2) cells. Compared to wild-type mice, ITK knockout mice are resistant to asthma and exhibit reduced lung inflammation and decreased amounts of TH2-type cytokines in the bronchoalveolar lavage fluid. We found that a small-molecule selective inhibitor of ITK blocked TCR-mediated signaling in cultured TH2 cells, including the tyrosine phosphorylation of phospholipase C-γ1 (PLC-γ1) and the secretion of IL-2 and TH2-type cytokines. Unexpectedly, inhibition of the kinase activity of ITK during or after antigen rechallenge in an ovalbumin-induced mouse model of asthma failed to reduce airway hyperresponsiveness and inflammation. Rather, in mice, pharmacological inhibition of ITK resulted in T cell hyperplasia and the increased production of TH2-type cytokines. Thus, our studies predict that inhibition of the kinase activity of ITK may not be therapeutic in patients with asthma.
Collapse
Affiliation(s)
- Yonglian Sun
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Ivan Peng
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Joshua D Webster
- Department of Pathology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Eric Suto
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Justin Lesch
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Xiumin Wu
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Kate Senger
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - George Francis
- Department of Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Kathy Barrett
- Department of Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Jenna L Collier
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Jason D Burch
- Department of Discovery Chemistry, Genentech Inc., South San Francisco, CA 94080, USA
| | - Meijuan Zhou
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Yuan Chen
- Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, CA 94080, USA
| | - Connie Chan
- Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, CA 94080, USA
| | | | - Hai Ngu
- Department of Pathology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Olga Li
- Department of Biomarker Development, Genentech Inc., South San Francisco, CA 94080, USA
| | - Tracy Staton
- Department of Biomarker Development, Genentech Inc., South San Francisco, CA 94080, USA
| | - Charles Havnar
- Department of Pathology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Allan Jaochico
- Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, CA 94080, USA
| | - Janet Jackman
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Surinder Jeet
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Lorena Riol-Blanco
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Lawren C Wu
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - David F Choy
- Department of Immunology, Tissue Growth, and Repair Diagnostics Discovery, Genentech Inc., South San Francisco, CA 94080, USA
| | - Joseph R Arron
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Brent S McKenzie
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Nico Ghilardi
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | | | - Zhonghua Pei
- Department of Discovery Chemistry, Genentech Inc., South San Francisco, CA 94080, USA
| | - Jason DeVoss
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Cary D Austin
- Department of Pathology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Wyne P Lee
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA
| | - Ali A Zarrin
- Department of Immunology, Genentech Inc., South San Francisco, CA 94080, USA.
| |
Collapse
|
2
|
del Blanco B, García-Mariscal A, Wiest DL, Hernández-Munain C. Tcra enhancer activation by inducible transcription factors downstream of pre-TCR signaling. THE JOURNAL OF IMMUNOLOGY 2012; 188:3278-93. [PMID: 22357628 DOI: 10.4049/jimmunol.1100271] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The Tcra enhancer (Eα) is essential for pre-TCR-mediated activation of germline transcription and V(D)J recombination. Eα is considered an archetypical enhanceosome that acts through the functional synergy and cooperative binding of multiple transcription factors. Based on dimethylsulfate genomic footprinting experiments, there has been a long-standing paradox regarding Eα activation in the absence of differences in enhancer occupancy. Our data provide the molecular mechanism of Eα activation and an explanation of this paradox. We found that germline transcriptional activation of Tcra is dependent on constant phospholipase Cγ, as well as calcineurin- and MAPK/ERK-mediated signaling, indicating that inducible transcription factors are crucially involved. NFAT, AP-1, and early growth response factor 1, together with CREB-binding protein/p300 coactivators, bind to Eα as part of an active enhanceosome assembled during pre-TCR signaling. We favor a scenario in which the binding of lymphoid-restricted and constitutive transcription factors to Eα prior to its activation forms a regulatory scaffold to recruit factors induced by pre-TCR signaling. Thus, the combinatorial assembly of tissue- and signal-specific transcription factors dictates the Eα function. This mechanism for enhancer activation may represent a general paradigm in tissue-restricted and stimulus-responsive gene regulation.
Collapse
Affiliation(s)
- Beatriz del Blanco
- Departamento de Biología Celular e Inmunología, Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), Consejo Superior de Investigaciones Científicas, 18100-Armilla, Granada, Spain
| | | | | | | |
Collapse
|